Viral Resistance in Hepatitis B: Prevalence and Management

[Guest guest]

http://www.metapress.com/content/p35744543m64k553/

Journal Article

Viral Resistance in Hepatitis B: Prevalence and Management

Journal Current Gastroenterology Reports

Publisher Current Medicine Group LLC

ISSN 1522-8037 (Print) 1534-312X (Online)

DOI 10.1007/s11894-009-0088-1

Subject Group Medicine

Online Date Friday, February 05, 2010

Authors

Fred Poordad1 , Grace M. Chee2

1Cedars-Sinai Medical Center Geffen School of Medicine at UCLA, Hepatology

and Liver Transplantation 8635 West Third Street, Suite 1060 Los Angeles CA

90048 USA

2Cedars-Sinai Medical Center Hepatology and Liver Transplantation 8635 West

Third Street, Suite 1060 Los Angeles CA 90048 USA

Abstract

Abstract Hepatitis B is a DNA virus affecting hundreds of millions of

individuals worldwide. As the clinical sequelae of cirrhosis and hepatocellular

cancer are increasingly recognized to be related to viral levels, the impetus

increases to offer treatment to those previously not treated. With the

development of more robust antivirals with reasonable safety profiles, long-term

treatment is becoming more common. The oral nucleos(t)ide analogs have become

the preferred first-line therapies for most genotypes of hepatitis B. Five are

now available, all with different potencies and resistance profiles. Long-term

data spanning several years are now available for most compounds in this arena.

This article focuses on the common natural variants and those secondary to

nucleos(t)ide therapy, as well as diagnostic methods to detect resistance.

[Guest guest]

http://www.metapress.com/content/p35744543m64k553/

Journal Article

Viral Resistance in Hepatitis B: Prevalence and Management

Journal Current Gastroenterology Reports

Publisher Current Medicine Group LLC

ISSN 1522-8037 (Print) 1534-312X (Online)

DOI 10.1007/s11894-009-0088-1

Subject Group Medicine

Online Date Friday, February 05, 2010

Authors

Fred Poordad1 , Grace M. Chee2

1Cedars-Sinai Medical Center Geffen School of Medicine at UCLA, Hepatology

and Liver Transplantation 8635 West Third Street, Suite 1060 Los Angeles CA

90048 USA

2Cedars-Sinai Medical Center Hepatology and Liver Transplantation 8635 West

Third Street, Suite 1060 Los Angeles CA 90048 USA

Abstract

Abstract Hepatitis B is a DNA virus affecting hundreds of millions of

individuals worldwide. As the clinical sequelae of cirrhosis and hepatocellular

cancer are increasingly recognized to be related to viral levels, the impetus

increases to offer treatment to those previously not treated. With the

development of more robust antivirals with reasonable safety profiles, long-term

treatment is becoming more common. The oral nucleos(t)ide analogs have become

the preferred first-line therapies for most genotypes of hepatitis B. Five are

now available, all with different potencies and resistance profiles. Long-term

data spanning several years are now available for most compounds in this arena.

This article focuses on the common natural variants and those secondary to

nucleos(t)ide therapy, as well as diagnostic methods to detect resistance.